STOCKHOLM--(BUSINESS WIRE)--Regulatory News: The Swedish biotech company Karo Bio (Reuters: KARO.ST) today announced the publication of results from a clinical phase II trial evaluating the company’s liver selective thyroid hormone receptor agonist eprotirome and its ability to further reduce serum LDL cholesterol levels in statin-treated patients. The results are published in the March 11, 2010 edition of the New England Journal of Medicine (NEJM).
